Edwards Lifesciences v Meril Lifesciences (CFI, 18 September 2024)
| Date | 18 September 2024 |
|---|---|
| Court | CFI |
| Division | Nordic Baltic Regional Division |
| Type of action | Application RoP262.1 (b) |
| Registry reference | App_33316/2024 · ORD_36322/2024 |
| Parties | KIPA AB |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By a procedural order delivered on 18 September 2024 (UPC_CFI_8/2023, ACT_459769/2023, ORD_36465/2024), the Nordic-Baltic Regional Division (S. Johansson, presiding, K. Härmand, judge-rapporteur, R. Lopes, E. Papa) refused a request for access to all written pleadings and evidence in the action brought by Edwards Lifesciences Corporation against Meril Lifesciences PVT Limited, Meril GmbH, Smis International OÜ and Sormedica UAB for infringement of EP 2 628 464, and in the counterclaims. A single order disposes of the requests filed in the action and in the counterclaims (Nos 33316/2024 and 33491/2024 to 33494/2024). The applicant, whose name is redacted, described itself as a board member and investor in a cardiac implant technology company. Leave to appeal was granted.
Question
Can a member of the public relying on a competitor’s interest in the patent’s validity obtain access, under Rule 262.1(b), to the pleadings of pending proceedings?
Decision
The division accepted that the public has a general interest in access to written pleadings, which are in principle public subject to confidentiality (Art. 45 and 52 UPCA, Art. 47 of the Charter, Regulation No 1049/2001). The interest relied on was, however, very general, and the patent specification is already public. At this stage, protecting the integrity of the pending proceedings prevails. That interest usually lasts until the end of the proceedings, after which access may be more appropriate. The applicant’s precise field of activity mattered little. Costs were awarded against the applicant, and leave to appeal was granted because clarifying the law is of general interest.
Key points for practice
- Practical point: while proceedings are pending, an access request resting on a general competitor’s interest is unlikely to succeed, it is better made once the proceedings have ended.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 45 and 52
- Rules of Procedure
- Rule 262.1(b)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC), Confidentiality club.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantKIPA AB8 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application RoP262.1 (b)
- Outcome (Dhenne Avocats summary)
- La demande d'accès est rejetée : l'intérêt invoqué est trop général et l'intégrité de la procédure en cours prévaut jusqu'à la fin de l'instance, les frais sont mis à la charge du demandeur et l'appel est autorisé.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 628 464mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- KIPA (CFI, ORD_36466/2024, 18 September 2024) cites this decision
- KIPA (CFI, ORD_36456/2024, 18 September 2024) cites this decision
- KIPA (CFI, ORD_36468/2024, 18 September 2024) cites this decision
- KIPA (CFI, ORD_36465/2024, 18 September 2024) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 628 464 | Mentioned in the analysis (role not qualified) Also mentioned in 2 other decision(s): Edwards Lifesciences v Meril Lifesciences (CFI, 21 July 2025) · Edwards Lifesciences v Meril Lifesciences (CFI, 16 August 2024) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.